Epigenetic regulation of radioresistance: insights from preclinical and clinical studies

References

• Allen C, Her S, Jaffray DA. Radiotherapy for Cancer: present and Future. Adv Drug Deliv Rev. 2017;109:1–2.
   PubMed Web of Science ®Google Scholar
• Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461(7267):1071–1078.
   PubMed Web of Science ®Google Scholar
• Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 2011;11(4):239–253.
   PubMed Web of Science ®Google Scholar
• Wang JS, Wang HJ, Qian HL. Biological effects of radiation on cancer cells. Mil Med Res. 2018;5(1):20–018-0167–4.
   Google Scholar
• Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009;9(9):665–674.
   PubMed Web of Science ®Google Scholar
• Lin F, Luo J, Gao W, et al. COX-2 promotes breast cancer cell radioresistance via p38/MAPK-mediated cellular anti-apoptosis and invasiveness. Tumour Biol. 2013;34(5):2817–2826.
   PubMedGoogle Scholar
• Chang L, Graham PH, Hao J, et al. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell. Death Dis. 2013;4:e875.
   PubMed Web of Science ®Google Scholar
• Kutilin D. Genetic and epigenetic bases of prostate tumor cell radioresistance. Klin Onkol. 2021;34(3):220–234.
   PubMedGoogle Scholar
• Buckley AM, Lynam-Lennon N, O’Neill H, et al. Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers. Nat Rev Gastroenterol Hepatol. 2020;17(5):298–313.
   PubMed Web of Science ®Google Scholar
• Cabrera-Licona A, Perez-Anorve F-FM IX, Flores-Fortis M, et al. Deciphering the epigenetic network in cancer radioresistance. Radiother Oncol. 2021;159:48–59.
   PubMed Web of Science ®Google Scholar
• Valdagni R, Amichetti M. Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymph nodes in stage IV head and neck patients. Int J Radiat Oncol Biol Phys. 1994;28(1):163–169.
   PubMed Web of Science ®Google Scholar
• Owen JR, Ashton A, Bliss JM, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial [published correction appears in Lancet Oncol. 2006 Aug;7(8):620]. Lancet Oncol. 2006;7(6):467–471.
   PubMed Web of Science ®Google Scholar
• Tsujii H, Kamada T. A review of update clinical results of carbon ion radiotherapy. Jpn J Clin Oncol. 2012;42(8):670–685.
   PubMed Web of Science ®Google Scholar
• Kim W, Lee S, Seo D, et al. Cellular Stress Responses in Radiotherapy. Cells. 2019;8(9):10.3390/cells8091105.
   Web of Science ®Google Scholar
• Liz J, Esteller M. lncRNAs and microRNAs with a role in cancer development. Biochim Biophys Acta. 2016;1859(1):169–176.
   PubMed Web of Science ®Google Scholar
• O’Brien J, Hayder H, Zayed Y, et al. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol (Lausanne). 2018;9:402.
   PubMed Web of Science ®Google Scholar
• Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet. 2011;12(2):99–110.
   PubMed Web of Science ®Google Scholar
• Yap KL, Li S, Muñoz-Cabello AM, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell. 2010;38(5):662–674.
   PubMed Web of Science ®Google Scholar
• Zhou X, Gao W, Hua H, et al. LncRNA-BLACAT1 Facilitates Proliferation, Migration and Aerobic Glycolysis of Pancreatic Cancer Cells by Repressing CDKN1C via EZH2-Induced H3K27me3. Front Oncol. 2020;10:539805.
   PubMed Web of Science ®Google Scholar
• Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013;152(6):1298–1307.
   PubMed Web of Science ®Google Scholar
• Li S, Shen L, Chen KN. Association between H3K4 methylation and cancer prognosis: a meta-analysis. Thorac Cancer. 2018;9(7):794–799.
   PubMed Web of Science ®Google Scholar
• Alaskhar Alhamwe B, Khalaila R, Wolf J, et al. Histone modifications and their role in epigenetics of atopy and allergic diseases. Allergy Asthma Clin. Immunol. 2018;14(1):39–018-0259–4. eCollection 2018.
   Google Scholar
• Chang S, Yim S, Park H. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism. Exp Mol Med. 2019;51(6):1–17.
   Google Scholar
• Audia JE, Campbell RM. Histone Modifications and Cancer. Cold Spring Harb Perspect. Biol. 2016;8(4):a019521.
   PubMed Web of Science ®Google Scholar
• Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 1998;12(5):599–606.
   PubMed Web of Science ®Google Scholar
• Sterling J, Menezes SV, Abbassi RH, et al. Histone lysine demethylases and their functions in cancer. Int J Cancer. 2020. DOI:10.1002/ijc.33375
   PubMed Web of Science ®Google Scholar
• Morera L, Lubbert M, Jung M. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy. Clin Epigenetics. 2016;8(1):57–016-0223–4. eCollection 2016.
   Google Scholar
• Kaniskan HU, Martini ML, Jin J. Inhibitors of Protein Methyltransferases and Demethylases. Chem Rev. 2018;118(3):989–1068.
   PubMed Web of Science ®Google Scholar
• Hyun K, Jeon J, Park K, et al. Writing, erasing and reading histone lysine methylations. Exp Mol Med. 2017;49(4):e324.
   PubMed Web of Science ®Google Scholar
• Hashimoto H, Vertino PM, Cheng X. Molecular coupling of DNA methylation and histone methylation. Epigenomics. 2010;2(5):657–669.
   PubMed Web of Science ®Google Scholar
• Jin B, Robertson KD. DNA methyltransferases, DNA damage repair, and cancer. Adv Exp Med Biol. 2013;754:3–29.
   PubMed Web of Science ®Google Scholar
• Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology. 2013;38(1):23–38.
   PubMed Web of Science ®Google Scholar
• Jeggo PA, Geuting V, Löbrich M. The role of homologous recombination in radiation-induced double-strand break repair. Radiother Oncol. 2011;101(1):7–12.
   PubMed Web of Science ®Google Scholar
• Mukherjee K, English N, Meers C, et al. Systematic analysis of linker histone PTM hotspots reveals phosphorylation sites that modulate homologous recombination and DSB repair. DNA Repair (Amst). 2020;86:102763.
   PubMed Web of Science ®Google Scholar
• Roth DB, Wilson JH. Relative rates of homologous and nonhomologous recombination in transfected DNA. Proc Natl Acad Sci U S A. 1985;82(10):3355–3359.
   PubMed Web of Science ®Google Scholar
• Yaping QI, Warmenhoven JW. Mechanistic Modelling of Slow and Fast NHEJ DNA Repair Pathways Following Radiation for G0/G1 Normal Tissue Cells. Cancers (Basel). English. 2021;13(9)2202. doi:10.3390/cancers13092202.
   PubMed Web of Science ®Google Scholar
• Lodovichi S, Bellè F, Cervelli T, et al. Effect of BRCA1 missense variants on gene reversion in DNA double-strand break repair mutants and cell cycle-arrested cells of Saccharomyces cerevisiae. Mutagenesis. 2020;35(2):189–195.
   PubMed Web of Science ®Google Scholar
• Mazur AK, Nguyen TS, Gladyshev E. Direct Homologous dsDNA-dsDNA Pairing: how, Where, and Why? J Mol Biol. 2020;432(3):737–744.
   PubMed Web of Science ®Google Scholar
• Savic V, Yin B, Maas NL, et al. Formation of dynamic gamma-H2AX domains along broken DNA strands is distinctly regulated by ATM and MDC1 and dependent upon H2AX densities in chromatin. Mol Cell. 2009;34(3):298–310.
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(4):928–942.
   PubMed Web of Science ®Google Scholar
• Takemura H, Rao VA, Sordet O, et al. Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks. J Biol Chem. 2006;281(41):30814–30823.
   PubMed Web of Science ®Google Scholar
• Morgan MA, Lawrence TS. Molecular Pathways: overcoming Radiation Resistance by Targeting DNA Damage Response Pathways. Clin Cancer Res. 2015;21(13):2898–2904.
   PubMed Web of Science ®Google Scholar
• Wan G, Mathur R, Hu X, et al. Lu X. miRNA response to DNA damage. Trends Biochem Sci. 2011;36(9):478–484.
   PubMed Web of Science ®Google Scholar
• Hu H, Du L, Nagabayashi G, et al. ATM is down-regulated by N-Myc-regulated microRNA-421. Proc Natl Acad Sci U S A. 2010;107(4):1506–1511.
   PubMed Web of Science ®Google Scholar
• Lal A, Pan Y, Navarro F, et al. miR-24-mediated downregulation of H2AX suppresses DNA repair in terminally differentiated blood cells. Nat Struct Mol Biol. 2009;16(5):492–498.
   PubMed Web of Science ®Google Scholar
• Guo P, Lan J, Ge J, et al. MiR-26a enhances the radiosensitivity of glioblastoma multiforme cells through targeting of ataxia-telangiectasia mutated. Exp Cell Res. 2014;320(2):200–208.
   PubMed Web of Science ®Google Scholar
• Xie F, Xiao W, Tian Y, et al. MicroRNA-195-3p inhibits cyclin dependent kinase 1 to induce radiosensitivity in nasopharyngeal carcinoma. Bioengineered. 2021;12(1):7325–7334.
   PubMed Web of Science ®Google Scholar
• Qian L, Fei Q, Zhang H, et al. lncRNA HOTAIR Promotes DNA Repair and Radioresistance of Breast Cancer via EZH2. DNA Cell Biol. 2020;10(1089). [published online ahead of print, Nov 2 2020].
   Google Scholar
• Zhang X, Ma X, Wang Q, et al. EZH2 targeting to improve the sensitivity of acquired radio-resistance bladder cancer cells. Transl Oncol. 2022;16:101316.
   PubMed Web of Science ®Google Scholar
• Sanese P, Fasano C, Buscemi G, et al. Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality. iScience. 2020;23(10):101604.
   PubMed Web of Science ®Google Scholar
• Chen YJ, Tsai CH, Wang PY, et al. SMYD3 Promotes Homologous Recombination via Regulation of H3K4-mediated Gene Expression. Sci Rep. 2017;7(1):3842–017-03385–6.
   Google Scholar
• Lou Z, Chini CC, Minter-Dykhouse K, et al. Mediator of DNA damage checkpoint protein 1 regulates BRCA1 localization and phosphorylation in DNA damage checkpoint control. J Biol Chem. 2003;278(16):13599–13602.
   PubMed Web of Science ®Google Scholar
• Fotouhi Ghiam A, Taeb S, Huang X, et al. Long non-coding RNA urothelial carcinoma associated 1 (UCA1) mediates radiation response in prostate cancer. Oncotarget. 2017;8(3):4668–4689.
   PubMedGoogle Scholar
• Tang Y, Cui Y, Li Z, et al. Radiation-induced miR-208a increases the proliferation and radioresistance by targeting p21 in human lung cancer cells. J Exp Clin Cancer Res. 2016;35(1):7–016-0285–3.
   Google Scholar
• Newman EM, Morgan RJ, Kummar S, et al. A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2’-deoxycytidine, administered with tetrahydrouridine. Cancer Chemother Pharmacol. 2015;75(3):537–546.
   PubMed Web of Science ®Google Scholar
• Coyne GO, Wang L, Zlott J, et al. Intravenous 5-fluoro-2’-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2020;85(5):979–993.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Tilly H, Chaidos A, et al., Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21(11):1433–1442. .
   PubMed Web of Science ®Google Scholar
• Ni M, Li J, Zhao H, et al. BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair. Oncogene. 2021;40(15):2711–2724.
   PubMed Web of Science ®Google Scholar
• Wang J, Cheng P, Pavlyukov MS, et al. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2. J Clin Invest. 2020;130(11):6187.
   PubMed Web of Science ®Google Scholar
• Qian L, Fei Q, Zhang H, et al. lncRNA HOTAIR Promotes DNA Repair and Radioresistance of Breast Cancer via EZH2. DNA Cell Biol. 2020;39(12):2166–2173.
   Web of Science ®Google Scholar
• Galloway TJ, Wirth LJ, Colevas AD, et al. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res off J Am Assoc Cancer Res. 2015;21(7):1566–1573.
   PubMed Web of Science ®Google Scholar
• Munshi A, Kurland JF, Nishikawa T, et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res. 2005;11(13):4912–4922.
   PubMed Web of Science ®Google Scholar
• Munshi A, Tanaka T, Hobbs ML, et al. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther. 2006;5(8):1967–1974.
   PubMed Web of Science ®Google Scholar
• Karagiannis TC, El-Osta A. Modulation of cellular radiation responses by histone deacetylase inhibitors. Oncogene. 2006;25(28):3885–3893.
   PubMed Web of Science ®Google Scholar
• Ree AH, Dueland S, Folkvord S, et al. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol. 2010;11(5):459–464.
   PubMed Web of Science ®Google Scholar
• Galanis E, Jaeckle KA, Maurer MJ, et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study [published correction appears in J Clin Oncol. 2009 Jul 1;27(19):3262-3]. J Clin Oncol. 2009;27(12):2052–2058.
   PubMed Web of Science ®Google Scholar
• Shi W, Lawrence YR, Choy H, et al. Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial. J Neurooncol. 2014;118(2):313–319.
   PubMed Web of Science ®Google Scholar
• Shi W, Palmer JD, Werner-Wasik M, et al. Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas. J Neurooncol. 2016;127(3):535–539.
   PubMed Web of Science ®Google Scholar
• Braicu C, Buse M, Busuioc C, et al. A Comprehensive Review on MAPK: a Promising Therapeutic Target in Cancer. Cancers (Basel). 2019;11(10):10.3390/cancers11101618.
   Web of Science ®Google Scholar
• Brunet A, Roux D, Lenormand P, et al. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J. 1999;18(3):664–674.
   PubMed Web of Science ®Google Scholar
• Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors. 2006;24(1):21–44.
   PubMed Web of Science ®Google Scholar
• Affolter A, Drigotas M, Fruth K, et al. Increased radioresistance via G12S K-Ras by compensatory upregulation of MAPK and PI3K pathways in epithelial cancer. Head Neck. 2013;35(2):220–228.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Y, Zhou D, et al. Radiation-induced YAP activation confers glioma radioresistance via promoting FGF2 transcription and DNA damage repair. Oncogene. 2021;40(27):4580–4591.
   PubMed Web of Science ®Google Scholar
• Paramanantham A, Jung EJ, Go SI, et al. Activated ERK Signaling Is One of the Major Hub Signals Related to the Acquisition of Radiotherapy-Resistant MDA-MB-231 Breast Cancer Cells. Int J Mol Sci. 2021;22(9):10.3390/ijms22094940.
   Web of Science ®Google Scholar
• Ray-David H, Romeo Y, Lavoie G, et al. RSK promotes G2 DNA damage checkpoint silencing and participates in melanoma chemoresistance. Oncogene. 2013;32(38):4480–4489.
   PubMed Web of Science ®Google Scholar
• Cea M, Cagnetta A, Adamia S, et al., Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood. 2016;127(9):1138–1150. .
   PubMed Web of Science ®Google Scholar
• Rottapel R, Ilangumaran S, Neale C, et al. The tumor suppressor activity of SOCS-1. Oncogene. 2002;21(28):4351–4362.
   PubMed Web of Science ®Google Scholar
• Yoshikawa H, Matsubara K, Qian GS, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet. 2001;28(1):29–35.
   PubMed Web of Science ®Google Scholar
• Fukushima N, Sato N, Sahin F, et al. Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms. Br J Cancer. 2003;89(2):338–343.
   PubMed Web of Science ®Google Scholar
• Cabral LKD, Reyes PAC, Croce LS, et al. The Relevance of SOCS1 Methylation and Epigenetic Therapy in Diverse Cell Populations of Hepatocellular Carcinoma. Diagnostics (Basel). 2021;11(10):10.3390/diagnostics11101825.
   PubMedGoogle Scholar
• Fuks F, Burgers WA, Brehm A, et al. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet. 2000;24(1):88–91.
   PubMed Web of Science ®Google Scholar
• Xiong H, Du W, Zhang Y-J, et al. Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells. Mol Carcinog. 2012;51(2):174–184.
   PubMed Web of Science ®Google Scholar
• Kim MH, Kim MS, Kim W, et al. Suppressor of cytokine signaling (SOCS) genes are silenced by DNA hypermethylation and histone deacetylation and regulate response to radiotherapy in cervical cancer cells. PLoS One. 2015;10(4):e0123133.
   PubMed Web of Science ®Google Scholar
• Zhou H, Miki R, Eeva M, et al. Reciprocal regulation of SOCS 1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme. Clin Cancer Res. 2007;13(8):2344–2353.
   PubMed Web of Science ®Google Scholar
• Morel D, Jeffery D, Aspeslagh S, et al. Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise. Nat Rev Clin Oncol. 2020;17(2):91–107.
   PubMed Web of Science ®Google Scholar
• Mirzoeva OK, Das D, Heiser LM, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 2009;69(2):565–572.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Catley L, Yasui H, et al., Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006;107(10):4053–4062. .
   PubMed Web of Science ®Google Scholar
• Ogata A, Chauhan D, Teoh G, et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol. 1997;159(5):2212–2221.
   PubMed Web of Science ®Google Scholar
• Ogata A, Chauhan D, Urashima M, et al. Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells. Clin Cancer Res. 1997;3(6):1017–1022.
   PubMed Web of Science ®Google Scholar
• Dent P, Reardon DB, Park JS, et al. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell. 1999;10(8):2493–2506.
   PubMed Web of Science ®Google Scholar
• Qiao L, Yacoub A, McKinstry R, et al. Pharmocologic inhibitors of the mitogen activated protein kinase cascade have the potential to interact with ionizing radiation exposure to induce cell death in carcinoma cells by multiple mechanisms. Cancer. Biol. Ther. 2002;1(2):168–176.
   PubMed Web of Science ®Google Scholar
• ME U, EJ C, WP S 3rd, et al. Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition. Clin. Cancer Res. 2011;17(15):5038–5047.
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Kakefuda R, Tajima N, et al. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol. 2011;39(1):23–31.
   PubMed Web of Science ®Google Scholar
• Wu C, Williams TM, Robb R, et al. Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. Clin Cancer Res. 2020;26(13):3117–3125.
   PubMed Web of Science ®Google Scholar
• Estrada-Bernal A, Chatterjee M, Haque SJ, et al. MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways. Cell Cycle. 2015;14(23):3713–3724.
   PubMed Web of Science ®Google Scholar
• Grimminger PP, Danenberg P, Dellas K, et al. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer. Clin Cancer Res. 2011;17(10):3469–3477.
   PubMed Web of Science ®Google Scholar
• Duldulao MP, Lee W, Nelson RA, et al. Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma. Ann Surg Oncol. 2013;20(7):2166–2171.
   PubMed Web of Science ®Google Scholar
• Cassidy RJ, Zhang X, Patel PR, et al. Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy. Cancer. 2017;123(19):3681–3690.
   PubMed Web of Science ®Google Scholar
• Franke TF. PI3K/Akt: getting it right matters. Oncogene. 2008;27(50):6473–6488.
   PubMed Web of Science ®Google Scholar
• Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91(2):231–241.
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002;21(37):5673–5683.
   PubMed Web of Science ®Google Scholar
• Fresno Vara JA, Casado E, de Castro J, et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30(2):193–204.
   PubMed Web of Science ®Google Scholar
• Bozulic L, Surucu B, Hynx D, et al. PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell. 2008;30(2):203–213.
   PubMed Web of Science ®Google Scholar
• Feng J, Park J, Cron P, et al. Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem. 2004;279(39):41189–41196.
   PubMed Web of Science ®Google Scholar
• Chen CY, Chen J, He L, et al. PTEN: tumor Suppressor and Metabolic Regulator. Front Endocrinol (Lausanne). 2018;9:338.
   PubMed Web of Science ®Google Scholar
• Jiang L, He C, Zhang X, et al. MiR-193b-5p inhibits proliferation and enhances radio-sensitivity by downregulating the AKT/mTOR signaling pathway in tongue cancer. Transl Cancer Res. 2020;9(3):1851–1860.
   PubMed Web of Science ®Google Scholar
• Wei F, Liu Y, Guo Y, et al. miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer. Mol Cancer. 2013;12(1):81–4598-12–81.
   Google Scholar
• Hu Z, Zhou S, Luo H, et al. miRNA-17 promotes nasopharyngeal carcinoma radioresistance by targeting PTEN/AKT. Int J Clin Exp Pathol. 2019;12(1):229–240.
   PubMed Web of Science ®Google Scholar
• Gwak HS, Kim TH, Jo GH, et al. Silencing of microRNA-21 confers radio-sensitivity through inhibition of the PI3K/AKT pathway and enhancing autophagy in malignant glioma cell lines. PLoS One. 2012;7(10):e47449.
   PubMed Web of Science ®Google Scholar
• Song W, Zhang J, Xia Q, et al. Down-regulated lncRNA TP73-AS1 reduces radioresistance in hepatocellular carcinoma via the PTEN/Akt signaling pathway. Cell Cycle. 2019;18(22):3177–3188.
   PubMed Web of Science ®Google Scholar
• Benayoun BA, Pollina EA, Ucar D, et al. H3K4me3 breadth is linked to cell identity and transcriptional consistency [published correction appears in Cell. 2015 Nov 19;163(5):1281-6]. Cell. 2014;158(3):673–688.
   PubMed Web of Science ®Google Scholar
• Barski A, Cuddapah S, Cui K, et al. High-resolution profiling of histone methylations in the human genome. Cell. 2007;129(4):823–837.
   PubMed Web of Science ®Google Scholar
• Ma X, Zhou J, Liu J, et al. LncRNA ANCR promotes proliferation and radiation resistance of nasopharyngeal carcinoma by inhibiting PTEN expression. Onco Targets Ther. 2018;11:8399–8408.
   PubMed Web of Science ®Google Scholar
• Avan A, Narayan R, Giovannetti E, et al. Role of Akt signaling in resistance to DNA-targeted therapy. World J. Clin. Oncol. 2016;7(5):352–369.
   PubMedGoogle Scholar
• Myers AP, Konstantinopoulos PA, Barry WT, et al. Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. Int J Cancer. 2020;147(2):413–422.
   PubMed Web of Science ®Google Scholar
• Shariati M, Meric-Bernstam F. Targeting AKT for cancer therapy. Expert Opin Investig Drugs. 2019;28(11):977–988.
   PubMed Web of Science ®Google Scholar
• Liu WL, Gao M, Tzen KY, et al. Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma. Oncotarget. 2014;5(11):3662–3672.
   PubMedGoogle Scholar
• Konstantinidou G, Bey EA, Rabellino A, et al., Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res. 2009;69(19):7644–7652. .
   PubMed Web of Science ®Google Scholar
• Del Alcazar Cr G, Hardebeck MC, Mukherjee B, et al. Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. Clin Cancer Res. 2014;20(5):1235–1248.
   PubMed Web of Science ®Google Scholar
• Chen YH, Wei MF, Wang CW, et al. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer. Cancer Lett. 2015;357(2):582–590.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008;14(12):1351–1356.
   PubMed Web of Science ®Google Scholar
• Waqar SN, Robinson C, Bradley J, et al. A phase I study of temsirolimus and thoracic radiation in non-small-cell lung cancer. Clin Lung Cancer. 2014;15(2):119–123.
   PubMed Web of Science ®Google Scholar
• Narayan V, Vapiwala N, Mick R, et al. Phase 1 Trial of Everolimus and Radiation Therapy for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy. Int J Radiat Oncol Biol Phys. 2017;97(2):355–361.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent Mj, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.
   PubMed Web of Science ®Google Scholar
• Mandell JW, Hussaini IM, Zecevic M, et al. In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. Am J Pathol. 1998;153(5):1411–1423.
   PubMed Web of Science ®Google Scholar
• Schiff D, Jaeckle KA, Anderson SK, et al. Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: north Central Cancer Treatment Group Study/Alliance N0572. Cancer. 2018;124(7):1455–1463.
   PubMed Web of Science ®Google Scholar
• Krauze AV, Myrehaug SD, Chang MG, et al. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma. Int J Radiat Oncol Biol Phys. 2015;92(5):986–992.
   PubMed Web of Science ®Google Scholar
• Galanis E, Anderson SK, Miller CR, et al. Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro Oncol. 2018;20(4):546–556.
   PubMed Web of Science ®Google Scholar
• Kondapaka SB, Singh SS, Dasmahapatra GP, et al. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol. Cancer. Ther. 2003;2(11):1093–1103.
   PubMed Web of Science ®Google Scholar
• Kaley TJ, Panageas KS, Mellinghoff IK, et al. Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. J Neurooncol. 2019;144(2):403–407.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Shichino H, Kawamoto H, et al. Phase I study of perifosine monotherapy in patients with recurrent or refractory neuroblastoma. Pediatr Blood Cancer. 2017 [Epub May 18];64(11).
   Web of Science ®Google Scholar
• Vink SR, Schellens JH, Beijnen JH, et al. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours. Radiother Oncol. 2006;80(2):207–213.
   PubMed Web of Science ®Google Scholar
• Baskar R, Lee KA, Yeo R, et al. Cancer and radiation therapy: current advances and future directions. Int J Med Sci. 2012;9(3):193–199.
   PubMed Web of Science ®Google Scholar
• Jones B, Dale RG, Finst P, et al. Biological equivalent dose assessment of the consequences of hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47(5):1379–1384.
   PubMed Web of Science ®Google Scholar
• Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086–1094.
   PubMed Web of Science ®Google Scholar
• Angelov L, Mohammadi AM, Bennett EE, et al. Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm. J Neurosurg. 2018;129(2):366–382.
   PubMed Web of Science ®Google Scholar
• Pessina, F, Cozzi, L. “Hypo-fractionated stereotactic radiotherapy alone using volumetric modulated arc therapy for patients with single, large brain metastases unsuitable for surgical.
   Google Scholar
• Lo SS, Fakiris AJ, Chang EL, et al. Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol. 2010;7(1):44–54.
   PubMed Web of Science ®Google Scholar
• Zeng KL, Myrehaug S, Soliman H, et al. Mature Local Control and Reirradiation Rates Comparing Spine Stereotactic Body Radiation Therapy with Conventional Palliative External Beam Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022;114(2):293–300.
   PubMed Web of Science ®Google Scholar
• Yorke E, Gelblum D, Ford E, et al. Patient safety in external beam radiation therapy. AJR Am J Roentgenol. 2011;196(4):768–772.
   PubMed Web of Science ®Google Scholar
• van de Kamp, Heemskerk, van de Kamp G, et al. DNA Double Strand Break Repair Pathways in Response to Different Types of Ionizing Radiation. Front Genet. 30 Sep. 2021;12:738230.
   PubMed Web of Science ®Google Scholar
• Daly-Schveitzer N, Juliéron M, Gan Tao Y, et al. Intensity-modulated radiation therapy (IMRT): toward a new standard for radiation therapy of head and neck cancer? Eur Ann Otorhinolaryngol Head Neck Dis. 2011;128(5):241–247.
   PubMed Web of Science ®Google Scholar
• Wai Tong N, But B, Wong CHL, et al. Particle beam therapy for nasopharyngeal cancer: a systematic review and meta-analysis. Clin Transl Radiat Oncol. 23 Aug. 2022;37:41–56.
   PubMed Web of Science ®Google Scholar
• Gunn GB, Blanchard P, Garden AS, et al. Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. Int J Radiat Oncol Biol Phys. 2016;95(1):360–367.
   PubMed Web of Science ®Google Scholar
• Lewis GD, Holliday EB, Kocak-Uzel E, et al. Intensity-modulated proton therapy for nasopharyngeal carcinoma: decreased radiation dose to normal structures and encouraging clinical outcomes. Head Neck. 2016;38(Suppl S1):E1886–95.
   PubMedGoogle Scholar
• Takahashi A, Matsumoto H, Yuki K, et al. High-LET radiation enhanced apoptosis but not necrosis regardless of p53 status. Int J Radiat Oncol Biol Phys. 2004;60(2):591–597.
   PubMed Web of Science ®Google Scholar
• Tsujii H, Kamada T. A review of update clinical results of carbon ion radiotherapy. Jpn J Clin Oncol. 2012;42(8):670–685.
   PubMed Web of Science ®Google Scholar
• Tsujii H, Mizoe J-E, Kamada T, et al. Overview of clinical experiences on carbon ion radiotherapy at NIRS. Radiother Oncol. 2004;73(Suppl 2):S41–9.
   PubMedGoogle Scholar
• Balosso J, Febvey-Combes O, Iung A, et al. A randomized controlled phase III study comparing hadrontherapy with carbon ions versus conventional radiotherapy - including photon and proton therapy - for the treatment of radioresistant tumors: the ETOILE trial. BMC Cancer. 23 May. 2022;22(1):575.
   PubMed Web of Science ®Google Scholar
• Spirou SV, Basini M, Lascialfari A, et al. Magnetic Hyperthermia and Radiation Therapy: radiobiological Principles and Current Practice †. Nanomaterials (Basel). 2018;8(6):401.
   PubMedGoogle Scholar
• Huilgol NG, Gupta S, Sridhar CR. Hyperthermia with radiation in the treatment of locally advanced head and neck cancer: a report of randomized trial. J Cancer Res Ther. 2010;6(4):492–496.
   PubMed Web of Science ®Google Scholar
• Gabriele P, Amichetti M, Orecchia R, et al. Hyperthermia and radiation therapy for inoperable or recurrent parotid carcinoma. A phase I/II study. Cancer. 1995;75(4):908–913.
   PubMed Web of Science ®Google Scholar
• Kameda-Smith MM, Subapanditha MK, Salim SK, et al. Differentiation of Brain Tumor Initiating Cells. Methods Mol Biol. 2019;1869:85–91.
   PubMedGoogle Scholar
• Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756–760.
   PubMed Web of Science ®Google Scholar
• Sangai T, Akcakanat A, Chen H, et al. Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res. 2012;18(20):5816–5828.
   PubMed Web of Science ®Google Scholar
• Xing Y, Lin NU, Maurer MA, et al. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019;21(1):78–019-1154–8.
   Google Scholar
• Zhang Y, Wang Z, Gemeinhart RA. Progress in microRNA delivery. J Control Release. 2013;172(3):962–974.
   PubMed Web of Science ®Google Scholar
• Gao Y, Ishiyama H, Sun M, et al. The alkylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo. Radiat Oncol. 2011;6(1):39–717X-6–39.
   Google Scholar
• Song M, Bode AM, Dong Z, et al. AKT as a Therapeutic Target for Cancer. Cancer Res. 2019;79(6):1019–1031.
   PubMed Web of Science ®Google Scholar
• Yang ZY, Yang F, Zhang YL, et al. LncRNA-ANCR down-regulation suppresses invasion and migration of colorectal cancer cells by regulating EZH2 expression. Cancer. Biomark. 2017;18(1):95–104
   PubMed Web of Science ®Google Scholar